title: Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
authors.affiliation: Department of Radiation Oncology, Robert Wood Johnson School of Medicine and Cooper University Hospital, Camden, NJ 08103, USA. sdibiase@dvullc.com
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Dibiase
authors.forename: Arif
authors.initials: A
authors.lastname: Hussain
authors.forename: Ritesh
authors.initials: R
authors.lastname: Kataria
authors.forename: Pradip
authors.initials: P
authors.lastname: Amin
authors.forename: Sunakshi
authors.initials: S
authors.lastname: Bassi
authors.forename: Nancy
authors.initials: N
authors.lastname: Dawson
authors.forename: Young
authors.initials: Y
authors.lastname: Kwok
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods; D017024:Chemotherapy, Adjuvant / Q000379:methods; D018572:Disease-Free Survival; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D010388:Pelvis; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D043823:Taxoids / Q000008:administration & dosage*
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen